The world has been kept in suspense since early 2020 by Coronavirus Disease 2019 (COVID-19), a multi-organ disease caused by the highly contagious severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2). Cephalalgia, the most frequent early symptom of COVID-19, is not only painful but is a disabling condition imposing substantial personal suffering, impaired quality of life, and economic burden (1). Headache in acute viral illness is seen as a consequence of the immune response, whereas the mechanism of action leading to persistence thereafter is not well understood.
Headache with SARS‐CoV‐2 infection: A matter of concern